The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC).
Elisabeth A. Quoix
Consultant or Advisory Role - Transgene (U)
Honoraria - Bristol-Myers Squibb; Lilly; Roche/Genentech; Transgene
John J. Nemunaitis
Stock Ownership - Gradalis
Tomasz Burzykowski
Consultant or Advisory Role - Transgene
Berangere Bastien
Employment or Leadership Position - Transgene
Stock Ownership - Transgene
Gisele Lacoste
Employment or Leadership Position - Transgene
Stock Ownership - Transgene